Tilray Medical, a global leader in medical cannabis, is participating in Cannabis Europa London 2026, a key forum for discussing medical cannabis regulation and patient access in Europe. The event gathers policymakers, healthcare professionals, and industry leaders to explore evidence-based approaches to cannabis policy, including clinical trials and public health data. Tilray's Director of International Medical Affairs, José Tempero, will join a panel on designing public policy through data and trials. Tilray also supports patient access through its UK-based Lyphe Clinic and continues to expand its global medical cannabis platform across more than 20 regulated markets.
The cannabis industry is expanding rapidly with cannabis now classified as a Class 3 substance, reducing legal barriers for operators. This shift allows for more research, product development, and growth opportunities for both cannabis producers and ...
Tilray Brands, a global leader in cannabis and consumer packaged goods, will announce its financial results for the fourth quarter and full fiscal year ending May 31, 2026, on July 28, 2026, after market close. The company will hold a live conference...
BrewDog Waterloo, England's largest pub owned by Tilray Brands, is set to host a major watch party for the England vs Argentina semifinal. The event promises an electric atmosphere with giant screens and passionate fans. Tilray's £1 million bar tab p...
